Targets › B6N
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2030.
Open in Phaseline: the race on B6N, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | PF-08052667 Anti-B6N antibody-drug conjugate | B6N | Phase 1 | Non-muscle Invasive Bladder Cancer | Jan 2030 |
Non-muscle Invasive Bladder Cancer (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.